Attendee search 

Founded by faculty from Tallinn University of Technology in Estonia, IoT Technologies is commercializing a decade of research focused on distributed sensing / computing technology. The technology was initially applied to defense applications (see Defendec (www.defendec.com)). We are now taking the technology to the healthcare domain, more specifically to wellness monitoring, helping family members, caregivers and physicians to obtain a better understanding of the health of the person.

Inveni Capital offers entrepreneurial venture capital to life science companies in Northern and Central Europe.

Inveni Capital, with offices in Helsinki, Finland and Munich, Germany, is a life science focused venture capital firm investing in early to growth stage pharmaceutical development and medical technology companies in Northern and Central Europe. 

Mendor - the new diabetes movement

Mendor is a diabetes technology company with two main products:
1. Mendor Discreet - a globally unique all-in-one integrated glucose meter
2. Mendor Balance - a cloud-based glucose profiling & diabetes management platform for clinics, HCPs & diabetics.

Our key partners include:
Menarini Diagnostics, Merck Serono, Sanofi & Lilly.

Our revenue history:
2011: 0,2M€
2012: 0,6M€
2013 01-07: 3,2M€

Company presentation with some more details:
https://www.dropbox.com/sh/ycp289w4g8wmqwn/0Yj457jnK8/Mendor_Company_Presentation-Aug_2013.pdf

Innokas Medical provides services on product development, manufacturing and life-cycle management for world class medical devices. We are focused on medical devices and have tailored our processes to meet the needed quality and regulatory requirements.

Bone Index Finland Ltd. provides patented, reliable and cost effective solution for the growing need of osteoporosis diagnostics at primary healthcare.

Quality and safety are essential part of our business. Bone Index Finland has ISO 13485 certified Quality System as a medical device manufacturer. Products manufactured by us fulfill the requirements of Medical Device Directive (MDD 93/42/EEC).

It is estimated that over 75% of osteoporotic patients are not diagnosed nor receive treatment for their condition because the diagnostics is done in special healthcare. Our solution to fight this problem, Bindex®, is validated against prevailing gold standard in diagnostics (axial DXA) at special healthcare by using international guidelines. Therefore Bindex® results are comparable to axial DXA.

By using the world’s first pocket size instrument for bone densitometry, Bindex®, the osteoporosis can be diagnosed wherever you want!